Physician profile
Xiaoming Dong
NPI 1265488340
$47,460.88
in general payments reported to CMS, 2019-2025
20 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.67 · 2020: $29.78 · 2021: $86.09 · 2022: $930 · 2023: $32.17 · 2024: $18K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $7,665 · Travel and Lodging: $6,035 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,810 · Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Consulting Fee | $7,665.00 |
| Travel and Lodging | $6,034.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,810.00 |
| Food and Beverage | $839.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31,478.29 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $14,608.89 | 2023-2025 | |
| Biogen, INC. | $905.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.01 | 2024-2025 | Hyqvia |
| Boston Scientific Corporation | $50.58 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.72 | 2024-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $43.26 | 2022 | |
| Acadia Pharmaceuticals INC | $35.83 | 2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $33.14 | 2020-2021 | |
| Celgene Corporation | $31.27 | 2024-2025 | Zeposia |
| Ucb, INC. | $28.89 | 2019-2025 | Rystiggo |
| Acorda Therapeutics, INC | $19.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.69 | 2023 | |
| Ge Healthcare | $17.35 | 2019 | |
| Octapharma USA, INC. | $16.22 | 2025 | Octagam Immune Globulin (Human) |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.99 | 2019 | |
| Sk Life Science, INC. | $14.96 | 2024 | |
| Mylan Specialty L.P. | $13.98 | 2024 | Glatiramer Acetate |
| Abbvie INC. | $13.55 | 2024 | |
| Adamas Pharmaceuticals, INC. | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoming Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.